Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron R Hansen

Showing results (21-30 of 172) with videos related to

Pageof 18
Sort By:
Molecular Oncology|August 28, 2014
Early phase clinical trials to identify optimal dosing and safetyNatalie Cook, Aaron R Hansen, Lillian L Siu, et al.
Nature|September 20, 2013
Tumour heterogeneity in the clinicPhilippe L Bedard, Aaron R Hansen, Mark J Ratain, et al.
Cancer Medicine|June 29, 2021
Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic reviewEoghan Malone, Reeta Barua, Nicholas Meti, et al.
Cancer|February 10, 2017
Determinants of the recommended phase 2 dose of molecular targeted agentsAaron R Hansen, Natalie Cook, Eitan Amir, et al.
Clinical Genitourinary Cancer|September 12, 2017
Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell TumorReeta Barua, Alexander Magony, Korosh Khalili, et al.
Cancer Discovery|April 3, 2021
The Future of Clinical Trial Design in OncologyAnna Spreafico, Aaron R Hansen, Albiruni R Abdul Razak, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 21, 2021
Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancerAmbica Parmar, Abdul Aziz Qazi, Audrius Stundzia, et al.
Urologic Oncology|October 22, 2022
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancerMary Mahler, Esmail Al-Ezzi, Noa Shani Shrem, et al.
The Oncologist|February 8, 2019
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item LibraryDaniel Shepshelovich, Kate McDonald, Anna Spreafico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Mark Yarchoan, Aaron R Hansen, et al.
Pageof 18

Showing results (21-30 of 172) with videos related to

Sort By:
Pageof 18
Molecular Oncology|August 28, 2014
Early phase clinical trials to identify optimal dosing and safetyNatalie Cook, Aaron R Hansen, Lillian L Siu, et al.
Nature|September 20, 2013
Tumour heterogeneity in the clinicPhilippe L Bedard, Aaron R Hansen, Mark J Ratain, et al.
Cancer Medicine|June 29, 2021
Quality of patient-reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic reviewEoghan Malone, Reeta Barua, Nicholas Meti, et al.
Cancer|February 10, 2017
Determinants of the recommended phase 2 dose of molecular targeted agentsAaron R Hansen, Natalie Cook, Eitan Amir, et al.
Clinical Genitourinary Cancer|September 12, 2017
Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell TumorReeta Barua, Alexander Magony, Korosh Khalili, et al.
Cancer Discovery|April 3, 2021
The Future of Clinical Trial Design in OncologyAnna Spreafico, Aaron R Hansen, Albiruni R Abdul Razak, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 21, 2021
Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancerAmbica Parmar, Abdul Aziz Qazi, Audrius Stundzia, et al.
Urologic Oncology|October 22, 2022
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancerMary Mahler, Esmail Al-Ezzi, Noa Shani Shrem, et al.
The Oncologist|February 8, 2019
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item LibraryDaniel Shepshelovich, Kate McDonald, Anna Spreafico, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2017
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful ActivityValsamo Anagnostou, Mark Yarchoan, Aaron R Hansen, et al.
Pageof 18